InspireMD Inc. (NSPR): Price and Financial Metrics

InspireMD Inc. (NSPR): $1.44

0.00 (0.00%)

POWR Rating

Component Grades













NSPR Stock Summary

  • INSPIREMD INC's market capitalization of $12,326,659 is ahead of merely 3.69% of US-listed equities.
  • The ratio of debt to operating expenses for INSPIREMD INC is higher than it is for about just 13.09% of US stocks.
  • NSPR's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 13.16% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to INSPIREMD INC are ONDS, EYPT, CLPT, IPGP, and SONO.
  • NSPR's SEC filings can be seen here. And to visit INSPIREMD INC's official web site, go to

NSPR Valuation Summary

  • In comparison to the median Healthcare stock, NSPR's price/earnings ratio is 103.57% lower, now standing at -0.7.
  • NSPR's price/earnings ratio has moved up 2494.8 over the prior 139 months.

Below are key valuation metrics over time for NSPR.

Stock Date P/S P/B P/E EV/EBIT
NSPR 2022-09-23 2.5 0.5 -0.7 -0.5
NSPR 2022-09-22 2.6 0.5 -0.8 -0.5
NSPR 2022-09-21 2.7 0.5 -0.8 -0.5
NSPR 2022-09-20 2.7 0.5 -0.8 -0.5
NSPR 2022-09-19 2.8 0.6 -0.8 -0.5
NSPR 2022-09-16 2.7 0.6 -0.8 -0.5

NSPR Growth Metrics

    Its year over year revenue growth rate is now at 90.15%.
  • Its 5 year revenue growth rate is now at 107.85%.
  • Its 3 year price growth rate is now at -96.82%.
Over the past 33 months, NSPR's revenue has gone up $1,635,000.

The table below shows NSPR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 5.165 -14.284 -17.285
2022-03-31 4.672 -13.721 -16.156
2021-12-31 4.495 -13.21 -14.918
2021-09-30 3.273 -12.509 -14.674
2021-06-30 3.182 -11.413 -12.836
2021-03-31 2.457 -10.368 -11.809

NSPR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NSPR has a Quality Grade of F, ranking ahead of 2.38% of graded US stocks.
  • NSPR's asset turnover comes in at 0.099 -- ranking 153rd of 186 Medical Equipment stocks.
  • NEPH, PODD, and COO are the stocks whose asset turnover ratios are most correlated with NSPR.

The table below shows NSPR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.099 0.087 -4.886
2021-03-31 0.099 -0.043 -5.025
2020-12-31 0.170 0.033 -4.722
2020-09-30 0.264 0.219 -4.531
2020-09-30 0.264 0.219 -4.531
2020-06-30 0.283 0.170 -4.563

NSPR Price Target

For more insight on analysts targets of NSPR, see our NSPR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.50 Average Broker Recommendation 1.5 (Moderate Buy)

NSPR Stock Price Chart Interactive Chart >

Price chart for NSPR

NSPR Price/Volume Stats

Current price $1.44 52-week high $4.65
Prev. close $1.44 52-week low $1.35
Day low $1.44 Volume 3,094
Day high $1.49 Avg. volume 22,956
50-day MA $1.76 Dividend yield N/A
200-day MA $2.34 Market Cap 11.99M

InspireMD Inc. (NSPR) Company Bio

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. is headquartered in Tel Aviv, Israel.

NSPR Latest News Stream

Event/Time News Detail
Loading, please wait...

NSPR Latest Social Stream

Loading social stream, please wait...

View Full NSPR Social Stream

Latest NSPR News From Around the Web

Below are the latest news stories about INSPIREMD INC that investors may wish to consider to help them evaluate NSPR as an investment opportunity.

InspireMD Announces Presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference

TEL AVIV, Israel, Sept. 13, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced that the company will deliver a presentation at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) Conference, which is being held September 16-19, 2022, at the Boston Convention and Exhibition Center in Boston, MA. Details of the presentation are as follows: Title:Endovascular Sequestration of High-Risk

Yahoo | September 13, 2022

NAMSA and InspireMD Announce Strategic Outsourcing Partnership to Accelerate New Product Development

TOLEDO, Ohio & TEL AVIV, Israel, September 08, 2022--NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, and InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for treatment of carotid artery disease and prevention of stroke, announced today that they have entered into a strategic outsourcing partnership to accelerate medical device development and commercialization.

Yahoo | September 8, 2022

InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update

- Generated 47.8% growth in CGuard™ revenue year-over-year - - Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission - - Announced that endovascular pioneer Dr. Juan Parodi has agreed to act as strategic advisor to the company - --Management to Host Investor Conference Call Today, August 9th, at 8:30am ET-- TEL AVIV, Israel, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Sys

Yahoo | August 9, 2022

InspireMD to Report Second Quarter 2022 Financial Results on August 9, 2022, and Provide Corporate Business Update

- Conference call and webcast to be held at 8:30 a.m. EDT - TEL AVIV, Israel, Aug. 02, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report second quarter 2022 financial results on Tuesday, August 9th, 2022, before the financial markets open. Management will host a conference call and webcast with the investment community at 8

Yahoo | August 2, 2022

InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

Credited with performing the first ever endovascular repair procedure in 1990TEL AVIV, Israel, July 14, 2022 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke, today announced the appointment of endovascular pioneer Dr. Juan Parodi as a strategic advisor to the Company. Marvin Slosman, Chief Executive Officer of InspireMD, commented, “Dr. Parodi’s world renowned achievements in the field of vascular surgery a

Yahoo | July 14, 2022

Read More 'NSPR' Stories Here

NSPR Price Returns

1-mo N/A
3-mo -29.06%
6-mo -53.40%
1-year -63.08%
3-year -91.65%
5-year -99.99%
YTD -52.32%
2021 -40.94%
2020 -68.44%
2019 -86.42%
2018 -96.45%
2017 -94.88%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4298 seconds.